{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:39:34Z","timestamp":1792798774663,"version":"4.5.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pathalys Pharma Inc"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["JASN"],"abstract":"\n Key Points<\/jats:title>\n \n \n \n These 2 phase 3 trials assessed upacicalcet, an intravenous calcimimetic, in hemodialysis patients with secondary hyperparathyroidism.<\/jats:p>\n <\/jats:list-item>\n \n \n \u226530% reduction in intact parathyroid hormone levels occurred in 42% (Parathyroid Hormone [PTH] Attenuation Trial in Hemodialysis-1) and 44% (Parathyroid Hormone [PTH] Attenuation Trial in Hemodialysis-2) with upacicalcet versus 17% and 17%, respectively, with placebo (strata-adjusted; both\n P<\/jats:italic>\n < 0.001).\n <\/jats:p>\n <\/jats:list-item>\n \n Asymptomatic hypocalcemia was more frequent with upacicalcet, and symptomatic hypocalcemia was infrequent; gastrointestinal events were similar to placebo.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n Secondary hyperparathyroidism is a common complication in patients with CKD undergoing hemodialysis. We examined the efficacy and safety of upacicalcet, an intravenous calcimimetic, versus placebo on serum intact parathyroid hormone (iPTH) levels in patients receiving hemodialysis.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis (PATH)-1 and PATH-2 were identical, randomized, phase 3, double-blind, placebo-controlled trials conducted in parallel in 768 patients receiving hemodialysis with secondary hyperparathyroidism and serum iPTH levels \u2265400 to \u22641500 pg\/ml. Participants received intravenous upacicalcet (\n n<\/jats:italic>\n =510) or placebo (\n n<\/jats:italic>\n =258) after hemodialysis for 27 weeks; dosing was titrated using iPTH and corrected serum calcium. Calcium supplementation or changes in active vitamin D sterols for corrected serum calcium <8.3 mg\/dl without hypocalcemia symptoms were restricted. The primary outcome was the proportion of participants achieving \u226530% decrease from baseline in mean iPTH during the efficacy assessment period, weeks 22\u201327.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The strata-adjusted proportions of participants achieving the primary outcome were significantly higher with upacicalcet versus placebo: in PATH-1, 42.1% versus 16.8%, for a difference in proportions of 25.3% (95% confidence interval, 16.2 to 34.5,\n P<\/jats:italic>\n < 0.001); in PATH-2, 43.5% versus 17.4%, for a difference in proportions of 26.1% (95% confidence interval, 17.4 to 34.8,\n P<\/jats:italic>\n < 0.001). Serious adverse events were similar between upacicalcet and placebo (PATH-1, 26% versus 24%; PATH-2, 23% versus 22%). Rates of gastrointestinal symptoms were similar between treatment groups. Corrected calcium <7.5 mg\/dl occurred in 31% versus 12% in PATH-1 and 45% versus 19% in PATH-2; dose interruptions occurred in 44% versus 24% and 52% versus 27%, respectively. Investigator-attributed symptomatic hypocalcemia was reported in 0.8% and 2% of upacicalcet-treated participants, respectively, and in no placebo patients.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n In 2 phase 3 trials, upacicalcet significantly reduced iPTH versus placebo. Asymptomatic hypocalcemia and dose interruptions were more frequent in patients receiving upacicalcet, while symptomatic hypocalcemia was infrequent and gastrointestinal adverse event rates were similar to placebo.<\/jats:p>\n <\/jats:sec>\n \n Clinical Trial registry name and registration number:<\/jats:title>\n PATH-1 NCT05832931 and PATH-2 NCT05836220.<\/jats:p>\n <\/jats:sec>","DOI":"10.1681\/asn.0000001285","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:00:09Z","timestamp":1792796409000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Upacicalcet in Hemodialysis Patients with Secondary Hyperparathyroidism"],"prefix":"10.1681","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8756-6637","authenticated-orcid":false,"given":"Jessica","family":"Kendrick","sequence":"first","affiliation":[{"name":"Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7214-1895","authenticated-orcid":false,"given":"Markus","family":"Ketteler","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine and Nephrology, Robert-Bosch-Hospital, Stuttgart, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1127-1442","authenticated-orcid":false,"given":"Myles","family":"Wolf","sequence":"additional","affiliation":[{"name":"Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York-Presbyterian\/Weill Cornell Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5716-0342","authenticated-orcid":false,"given":"Snezana","family":"Pesic","sequence":"additional","affiliation":[{"name":"Clinical Department of Nephrology and Metabolic Disorders With Dialysis \u201cProf. Dr. Vasilije Jovanovic\u201d Zvezdara Clinical Hospital Center, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3009-0898","authenticated-orcid":false,"given":"Biserka","family":"Tirmenstajn-Jankovic","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hemodialysis, Health Center Zajecar, Zajecar, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Zeig","sequence":"additional","affiliation":[{"name":"Memorial Healthcare System, Hollywood, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7445-3102","authenticated-orcid":false,"given":"Aaron","family":"Camp","sequence":"additional","affiliation":[{"name":"Launch Therapeutics, Raleigh, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Copeland","sequence":"additional","affiliation":[{"name":"Launch Therapeutics, Raleigh, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BT","family":"Slingsby","sequence":"additional","affiliation":[{"name":"Pathalys Pharma Inc., Raleigh, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Dehmel","sequence":"additional","affiliation":[{"name":"Pathalys Pharma Inc., Raleigh, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4646-7074","authenticated-orcid":false,"given":"Geoffrey","family":"Block","sequence":"additional","affiliation":[{"name":"US Renal Care, Inc, Plano, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"issue":"11","key":"B1-20261023","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int"},{"issue":"1","key":"B2-20261023","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-BMD) guideline update: what\u2019s changed and why it matters","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int."},{"issue":"6","key":"B3-20261023","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.semnephrol.2018.08.001","article-title":"Update on chronic kidney disease mineral and bone disorder in cardiovascular disease","volume":"38","author":"Lunyera","year":"2018","journal-title":"Semin Nephrol."},{"issue":"4","key":"B4-20261023","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5001514","article-title":"Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients","volume":"70","author":"Kalantar-Zadeh","year":"2006","journal-title":"Kidney Int."},{"issue":"15","key":"B5-20261023","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med."},{"issue":"3","key":"B6-20261023","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1681\/ASN.2004060512","article-title":"Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study","volume":"16","author":"Lindberg","year":"2005","journal-title":"J Am Soc Nephrol."},{"issue":"5","key":"B7-20261023","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.ajkd.2006.01.015","article-title":"Meta-analysis of biochemical and patient-level effects of calcimimetic therapy","volume":"47","author":"Strippoli","year":"2006","journal-title":"Am J Kidney Dis."},{"issue":"2","key":"B8-20261023","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jama.2016.19456","article-title":"Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials","volume":"317","author":"Block","year":"2017","journal-title":"JAMA."},{"issue":"2","key":"B9-20261023","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2016.19468","article-title":"Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial","volume":"317","author":"Block","year":"2017","journal-title":"JAMA."},{"issue":"4","key":"B10-20261023","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1124\/molpharm.122.000522","article-title":"Upacicalcet is a novel secondary hyperparathyroidism drug that targets the amino acid binding site of calcium-sensing receptor","volume":"102","author":"Sato","year":"2022","journal-title":"Mol Pharmacol."},{"key":"B11-20261023","doi-asserted-by":"crossref","first-page":"175936","DOI":"10.1016\/j.ejphar.2023.175936","article-title":"Pharmacological profile of upacicalcet, a novel positive allosteric modulator of calcium-sensing receptor, in vitro and in vivo","volume":"956","author":"Goto","year":"2023","journal-title":"Eur J Pharmacol."},{"issue":"2","key":"B12-20261023","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s40268-022-00385-4","article-title":"First-in-human phase I study of the novel injectable calcimimetic agent upacicalcet in healthy adult Japanese participants","volume":"22","author":"Koiwa","year":"2022","journal-title":"Drugs R D."},{"issue":"9","key":"B13-20261023","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s40262-022-01139-w","article-title":"First-in-patient phase I\/II study of upacicalcet in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: pharmacokinetic and pharmacodynamic properties","volume":"61","author":"Kazama","year":"2022","journal-title":"Clin Pharmacokinet."},{"issue":"13","key":"B14-20261023","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s40265-021-01578-y","article-title":"Upacicalcet: first approval","volume":"81","author":"Hoy","year":"2021","journal-title":"Drugs."},{"issue":"10","key":"B15-20261023","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.2215\/CJN.0000000000000253","article-title":"Efficacy and safety of upacicalcet in hemodialysis patients with secondary hyperparathyroidism: a randomized placebo-controlled trial","volume":"18","author":"Shigematsu","year":"2023","journal-title":"Clin J Am Soc Nephrol."},{"issue":"4 suppl 3","key":"B16-20261023","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","year":"2003","journal-title":"Am J Kidney Dis."},{"issue":"1","key":"B17-20261023","first-page":"1","article-title":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"7","author":"Ketteler","year":"2017","journal-title":"Kidney Int Suppl (2011)"},{"issue":"6","key":"B18-20261023","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/jcph.460","article-title":"Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis","volume":"55","author":"Chen","year":"2015","journal-title":"J Clin Pharmacol."},{"issue":"1","key":"B19-20261023","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.114.013876","article-title":"Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial","volume":"132","author":"Moe","year":"2015","journal-title":"Circulation."},{"issue":"1","key":"B20-20261023","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/ckj\/sfz034","article-title":"Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis","volume":"13","author":"Wolf","year":"2020","journal-title":"Clin Kidney J."},{"issue":"6","key":"B21-20261023","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Guti\u00e9rrez","year":"2008","journal-title":"N Engl J Med."},{"issue":"10","key":"B22-20261023","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1681\/ASN.2010121224","article-title":"FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis","volume":"22","author":"Kendrick","year":"2011","journal-title":"J Am Soc Nephrol."},{"issue":"23","key":"B23-20261023","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","article-title":"Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease","volume":"305","author":"Isakova","year":"2011","journal-title":"JAMA."},{"issue":"6","key":"B24-20261023","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2215\/CJN.03270314","article-title":"Effect of cinacalcet and vitamin D analogs on fibroblast growth factor-23 during the treatment of secondary hyperparathyroidism","volume":"10","author":"Sprague","year":"2015","journal-title":"Clin J Am Soc Nephrol."}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000001285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:00:13Z","timestamp":1792796413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000001285"}},"subtitle":["Two Randomized Clinical Trials"],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":24,"URL":"https:\/\/doi.org\/10.1681\/asn.0000001285","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"2026-08-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}